Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03985943
Registration number
NCT03985943
Ethics application status
Date submitted
11/06/2019
Date registered
14/06/2019
Date last updated
21/09/2023
Titles & IDs
Public title
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Query!
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Query!
Secondary ID [1]
0
0
RD.06.SPR.118161
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Moderate-to-Severe Atopic Dermatitis
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Nemolizumab
Placebo Comparator: Placebo - Placebo
Experimental: Nemolizumab - Nemolizumab Active
Treatment: Drugs: Placebo
Placebo
Treatment: Drugs: Nemolizumab
Nemolizumab
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of subjects with an IGA success (IGA of 0 or 1) and a = 2-point reduction
Query!
Assessment method [1]
0
0
IGA success rate defined as the proportion of subjects who achieve an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 16.
Query!
Timepoint [1]
0
0
Baseline to Week 16
Query!
Primary outcome [2]
0
0
Proportion of subjects with EASI-75
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline to Week 16
Query!
Secondary outcome [1]
0
0
Proportion of subjects with an improvement of PP NRS = 4
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 16
Query!
Secondary outcome [2]
0
0
Proportion of subjects with PP NRS < 2
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Week 16
Query!
Secondary outcome [3]
0
0
Proportion of subjects with an improvement of sleep disturbance NRS (SD NRS) = 4
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Week 16
Query!
Secondary outcome [4]
0
0
Proportion of subjects with an improvement of PP NRS = 4
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Week 4
Query!
Secondary outcome [5]
0
0
Proportion of subjects with PP NRS < 2
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Week 4
Query!
Secondary outcome [6]
0
0
Proportion of subjects with an improvement of PP NRS = 4
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Week 2
Query!
Secondary outcome [7]
0
0
Proportion of subjects with an improvement of PP NRS = 4
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Week 1
Query!
Secondary outcome [8]
0
0
Proportion of subjects with EASI-75 and improvement of PP NRS = 4
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Week 16
Query!
Secondary outcome [9]
0
0
Proportion of subjects with IGA success and improvement of PP NRS = 4
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Week 16
Query!
Eligibility
Key inclusion criteria
Key
- Male or female subjects aged = 12 years at the screening visit Note: Enrollment of
subjects aged 12 to 17 years has been opened after the IDMC has assessed interim
safety data from the phase 2 study (Protocol 116912) and provided recommendations to
the sponsor, who then determined the eligibility of this age group for enrollment in
the study
- Chronic AD that has been documented for at least 2 years
- EASI score = 16
- IGA score = 3
- AD involvement = 10% of BSA
- PPNRS score of at least 4.0 at the screening and baseline visit
- Documented recent history of inadequate response to topical medications (TCS with or
without TCI)
- Female subjects of childbearing potential (that is, fertile, following menarche and
until becoming postmenopausal unless permanently sterile) must agree either to be
strictly abstinent throughout the study and for 12 weeks after the last study drug
injection, or to use an adequate and approved method of contraception throughout the
study and for 12 weeks after the last study drug injection
Key
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Body weight < 30 kg
- Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical
study
- Cutaneous infection within 1 week before the baseline visit, any infection requiring
treatment with oral or parenteral antibiotics, antivirals, antiparasitics or
antifungals within 2 weeks before the baseline visit, or any confirmed or suspected
coronavirus disease (COVID)-19 infection within 2 weeks before the screening or
baseline visit Note: Subjects with chronic, stable use of prophylactic treatment for
recurrent herpes viral infection can be included in this clinical study
- History of hypersensitivity (including anaphylaxis) to an immunoglobulin product
(plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study drug
excipients
- Any clinically significant issue, based on investigator judgement
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/08/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
941
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Galderma Investigational Site 5441 - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Galderma Investigational Site 5759 - Kogarah
Query!
Recruitment hospital [3]
0
0
Galderma Investigational Site 6152 - Westmead
Query!
Recruitment hospital [4]
0
0
Galderma Investigational Site 5638 - Benowa
Query!
Recruitment hospital [5]
0
0
Galderma Investigational Site 6161 - Brisbane
Query!
Recruitment hospital [6]
0
0
Galderma Investigational Site 6159 - Woodville
Query!
Recruitment hospital [7]
0
0
Galderma Investigational Site 6131 - Carlton
Query!
Recruitment hospital [8]
0
0
Galderma Investigational Site 5366 - East Melbourne
Query!
Recruitment hospital [9]
0
0
Galderma Investigational Site 5458 - Parkville
Query!
Recruitment hospital [10]
0
0
Galderma Investigational Site 6160 - Parkville
Query!
Recruitment hospital [11]
0
0
Galderma Investigational Site 5453 - Fremantle
Query!
Recruitment hospital [12]
0
0
Galderma Investigational Site 6153 - Victoria Park
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
4217 - Benowa
Query!
Recruitment postcode(s) [5]
0
0
4102 - Brisbane
Query!
Recruitment postcode(s) [6]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [7]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [8]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [9]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [10]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [11]
0
0
6160 - Fremantle
Query!
Recruitment postcode(s) [12]
0
0
6100 - Victoria Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
District of Columbia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maine
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Montana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nevada
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Hampshire
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Mexico
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oklahoma
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Dakota
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Virginia
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Styria
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Wien
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Linz
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Vienna
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Alberta
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
British Columbia
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Ontario
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Niagara Falls
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ottawa
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Saint John
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Waterloo
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Brno
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Náchod
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Olomouc
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Prague
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Praha
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Hesse
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Niedersachesen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
NRW
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Schleswig-Holst
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Bad Bentheim
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Berlin
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Bielefeld
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Buxtehude
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Darmstadt
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Dülmen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Lubeck
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Münster
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Osnabrück
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Stuttgart
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Bucheon
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Busan
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Gyeonggi-do
Query!
Country [60]
0
0
Korea, Republic of
Query!
State/province [60]
0
0
Incheon
Query!
Country [61]
0
0
Korea, Republic of
Query!
State/province [61]
0
0
Seoul
Query!
Country [62]
0
0
Latvia
Query!
State/province [62]
0
0
Liepaja
Query!
Country [63]
0
0
Latvia
Query!
State/province [63]
0
0
Riga
Query!
Country [64]
0
0
Latvia
Query!
State/province [64]
0
0
Talsi
Query!
Country [65]
0
0
Lithuania
Query!
State/province [65]
0
0
Kaunas
Query!
Country [66]
0
0
Lithuania
Query!
State/province [66]
0
0
Klaipeda
Query!
Country [67]
0
0
Lithuania
Query!
State/province [67]
0
0
Vilnius
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Groningen
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Rotterdam
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Utrecht
Query!
Country [71]
0
0
New Zealand
Query!
State/province [71]
0
0
Hamilton
Query!
Country [72]
0
0
New Zealand
Query!
State/province [72]
0
0
Wellington
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Czestochowa
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Gdansk
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Gdynia
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Katowice
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Lublin
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Ostrowiec Swietokrzyski
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Poznan
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Rzeszów
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Szczecin
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Warszawa
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Wroclaw
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Lódz
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Alicante
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Barcelona
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Las Palmas De Gran Canaria
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Madrid
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Majadahonda
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Málaga
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Pamplona
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Valencia
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Barnsley
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
Blackpool
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Cannock
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Cardiff
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Chorley
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Dudley
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Edgbaston
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Glasgow
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Liverpool
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
London
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Manchester
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Newcastle
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Stockton-on-Tees
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Galderma R&D
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of the study is to assess the efficacy and safety of nemolizumab after a
16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic
dermatitis (AD) not adequately controlled with topical treatments.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03985943
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03985943
Download to PDF